Regulators abroad have also indicated plans to review COX-2 drugs.
Vioxx and a similar drug from Pfizer Inc., Celebrex, have been touted as ``super-aspirins'' in numerous TV commercials that have downplayed their known cardiovascular risks.
 "I believe this is a class effect," he said, meaning that the problem also applies to Celebrex and Pfizer's newer, similar drug, Bextra, which remain on the market.
 FitzGerald also challenged Pfizer's contention that no science shows increased risk from Celebrex.
